Abstract
Objective
To quantify reports made to the Food and Drug Administration Adverse Event Reporting
System (FAERS), create a demographic of patient reports, and examine the cluster of
symptoms to correlate consistency of postfinasteride syndrome (PFS) complaints. PFS
is a provisional diagnosis encompassing a cluster of sexual, physical, and psychological
and/or neurologic symptoms associated with 5-alpha reductase inhibitor use that emerge
or continue after discontinuation of medication.
Materials and Methods
FAERS dataset of 5-alpha reductase inhibitors from April 2011 to October 2014 was
obtained. Each FAERS report had 16 categories for completion, but not every report
was fully completed. Statistical analysis compared variables of interest between the
2 doses of finasteride (1 mg vs 5 mg).
Results
From FAERS, 2048 monotherapy cases were identified: 1581 of finasteride 1 mg, 240
of finasteride 5 mg, and 226 of unreported doses. Possibly related to labeling changes,
from 2011 to 2014, there was a significant increase in adverse events (AEs) reported
involving 1 mg dosing. Finasteride use was reported with many sexual AEs including
diminished libido, erectile dysfunction, and ejaculatory complaints. Other common
AEs included dermatologic, metabolic, and psychological and/or neurologic complaints.
There were more AE reports with the 1 mg dose than the 5 mg dose. One case of dutasteride
reported back pain, not generally attributed to PFS.
Conclusion
FAERS data suggests that finasteride exposure is reported with a diverse collection
of symptoms, particularly in younger men on 1 mg dosage compared to older men on 5
mg. Many of these complaints fall well out of the realm of previously established
AEs from long-term controlled studies.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Questions and Answers: Finasteride Label Changes. U.S. Department of Health & Human Services, 2012. (Accessed 6/15/15, at http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm)
- Whitehouse Station.Merk Sharp & Dohme Corp., NJ, USA2010 (October)
- The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.Adv Urol. 2012; 2012: 18
- Research Triangle Park NC, USA: GlaxoSmithKline;. 2008;
- Update on AUA guideline on the management of benign prostatic hyperplasia.J Urol. 2011; 185: 1793-1803
- Sexual Medicine Society of North America 5ARI Colloquium Registry Group, Meeting Transcript. Washington, D.C.2014
- (Accessed June 17, 2015, at)http://www.pfsfoundation.org/Date: 2013
- 5 alpha-reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis.Horm Mol Biol Clin Investig. 2014; 20: 73-80
- 5alpha-reductase type 1 modulates insulin sensitivity in men.J Clin Endocrinol Metab. 2014; 99: E1397-E1406
- Psychological aspects of hair disease.J Cosmet Dermatol. 2005; 4: 142-147
- Finasteride induced depression: a prospective study.BMC Clin Pharmacol. 2006; 6: 7
- Finasteride-induced depression: new insights into possible pathomechanisms.J Cosmet Dermatol. 2010; 9: 331-332
- Finasteride treatment inhibits adult hippocampal neurogenesis in male mice.Pharmacopsychiatry. 2010; 43: 174-178
- Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology.J Sex Med. 2013; 10: 2598-2603
- Depression circumstantially related to the administration of finasteride for androgenetic alopecia.J Dermatol. 2002; 29: 665-669
- Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.J Sex Med. 2011; 8: 872-884
- Finasteride treatment and neuroactive steroid formation.Prague Med Rep. 2009; 110: 222-230
- Neurosteroid metabolism in the human brain.Eur J Endocrinol Eur Feder Endocr Soc. 2001; 145: 669-679
- Neurosteroids, neuroactive steroids, and symptoms of affective disorders.Pharmacol Biochem Behav. 2006; 84: 644-655
- Persistent sexual side effects of finasteride: could they be permanent?.J Sex Med. 2012; 9: 2927-2932
- Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects.J Clin Psychiatry. 2012; 73: 1220-1223
- Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms.Am J Men Health. 2015; 9: 222-228
- Adverse event reporting in clinical trials of finasteride for androgenic alopecia: a meta-analysis.JAMA Dermatol. 2015; 151: 600-606
- The efficacy and safety of 5alpha-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride.J Dermatol Treat. 2014; 25: 156-161
- Persistent sexual dysfunction with finasteride 1 mg taken for hair loss.Pharmacotherapy. 2016; 36: 1180-1184
- Risk of erectile dysfunction associated with use of 5-alpha reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink.BMJ (Clin Res Ed). 2016; 354: i4823
- Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?.J Sex Med. 2007; 4: 1708-1712
- Whitehouse Station. Merk Sharp & Dohme Corp., NJ, USA04, 2012
Conner MW D-CC, Green LC, Armstrong SR, Taniguchi C, Tashijan AH, and Golan DE. Drug toxicity. principles of pharmacology: the pathophysiologic basis of drug therapy. 3 ed. 2011:56-70.
Article info
Publication history
Published online: June 27, 2018
Accepted:
June 14,
2018
Received in revised form:
May 31,
2018
Received:
September 20,
2017
Footnotes
Conflict of Interest: KTM: Retained as expert in litigation involving finasteride by Merck Inc. No other conflicts noted for other authors.
Identification
Copyright
© 2018 Elsevier Inc. All rights reserved.
